{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-088024","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.861848+00:00","generated_at":"2026-06-17T07:43:51.294361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Forte Biosciences reports FY 2022 net loss of $13.9M; advancing FB-102 toward clinic in late 2023/early 2024","bullets":["Net loss of $13.9M ($0.80/sh) vs $21.7M ($1.55/sh) in FY 2021; cash and equivalents $41.1M at year-end.","R&D expenses decreased to $5.6M from $13.9M due to termination of FB-401; G&A rose to $8.3M.","Lead candidate FB-102 for autoimmune diseases expected to enter clinic in late 2023 or early 2024.","Board appointed David Gryska (former CFO of Incyte and Celgene) in January 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-088024","json":"https://secwatch.observer/filing/0001193125-23-088024.json","markdown":"https://secwatch.observer/filing/0001193125-23-088024.md","text":"https://secwatch.observer/filing/0001193125-23-088024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/0001193125-23-088024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/d475905d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:43:51.294361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d32c0575f261b146c000b7d5b7c2237439938ae","claim":"Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2022 results: net income Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D, EPS net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively..","evidence_excerpt":"On March 31, 2023, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312523088024/0001193125-23-088024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Net income","value":"Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D"},{"label":"EPS","value":"net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}